Gsk Plc · LSE:GSK
Gsk — Investor Day (November 2021)
33 slides from Gsk's investor day presentation, Nov 29, 2021
Slide 1: Getting ahead of HIV
Meet GSK Management Getting ahead of HIV 29 November 2021 Conference call and webcast for analysts and institutional investors
Slide 2: Cautionary statement regarding forward-looking statements
Cautionary statement regarding forward-looking statements This presentation may contain forward-looking statements. Forward-looking statements give the Group’s current expectations or forecasts of future events. An investor can identify these statements by the fact that they do not relate strictly t
Slide 3: Agenda
Agenda David Redfern, ViiV Healthcare: a focused, competitive HIV Chief Strategy Officer, GSK company, backed by the scale of GSK Chairman, ViiV Healthcare Deborah Waterhouse, Reshaping and delivering HIV treatment and CEO, ViiV Healthcare prevention Dr Kimberly Smith, Leaders and disruptors in inno
Slide 4: Global specialist HIV company, focused on ending HIV/AIDS
Global specialist HIV company, focused on ending HIV/AIDS How we meet the challenge Our mission is to leave no person Leaders and Focused and Built on novel Strong commitment living with HIV disruptors in agile, backed by collaborations and to communities behind. innovation scale of GSK powerful par
Slide 5: Reshaping and delivering HIV treatment and prevention
Reshaping and delivering HIV treatment and prevention Ale, Living with HIV, Uruguay 5
Slide 6: Leading in HIV: Progress in 2021 and beyond
Leading in HIV Progress in 2021 and beyond Mid single digit % sales Innovation sales 29% Dovato on track to reach c.£3.5bn CAGR 2021-26 of sales in Q3 2021 £1bn of sales in 2022 Sales Q3 2021 YTD +4% Q3 2021 YTD Dovato driving growth With further potential beyond Strategic business development Innov
Slide 7: The shape of our HIV business
The shape of our HIV business 38 million people globally are living with HIV Sales Q3 2021 YTD by region (£m) 546 North America Europe 2,095 876 International £876m Of the 27.5m people on ARTs1 globally >18 million are on a dolutegravir based regimen First dispersible formulation of dolutegravir ava
Slide 8: Key trends shaping the £26bn HIV treatment and prevention market
1 Key trends shaping the £26bn HIV treatment and prevention market Delivering on significant unmet needs in HIV Continued HIV transmission Ageing population three quarters of PLHIV expected 1.5m new cases of to be aged 50+ by 20305,6 HIV per year2 COVID impacting progress2 Quality of life significan
Slide 9: Our business today
Our business Today Yulia, Living with HIV, St Petersburg, Russia 9
Slide 10: Delivering our pioneering portfolio
Delivering our pioneering portfolio Competitive commercial and medical execution Targeted and agile investment allocation ViiV leading share of voice vs. main competitor in major markets7 – c.90% of country spend focused in top-10 countries – Significant increase in SG&A over the past three years. F
Slide 11: Dovato driving growth
Dovato driving growth Innovation sales now 27% of the portfolio 27% £955m – Innovation sales £955m Q3 2021 YTD 16% – Up 71% Q3 2021 YTD vs. 2020 at £592m Cabenuva Rukobia CER driven by Dovato Dovato Juluca Innovation sales as % of total sales 2020 2021 All figures as reported externally: Sales at ac
Slide 12: Dovato: best-in-class two-drug regimen
Dovato: best-in-class two-drug regimen Dovato demonstrates non-inferior efficacy to three drug regimens in Phase III clinical trials1 Dovato demonstrates: – Powerful, durable efficacy and high barrier to resistance1 – Benefits across subgroups1 89 investigator sponsored studies Dovato included among
Slide 13: Shifting the paradigm towards LA treatment
Shifting the paradigm towards LA treatment LA injectable treatment market c.£4-5bn by 2030 Cabenuva: world’s 1st and only Momentum building for Cabenuva LA regimen for HIV treatment Launched in 11 markets globally – Gold standard status because of potency, long-term tolerability and barrier to resis
Slide 14: Shifting the paradigm towards LA for pre-exposure prophylaxis (PrEP)
Shifting the paradigm towards LA for pre-exposure prophylaxis (PrEP) Cabotegravir: 1st LA regimen for HIV prevention LA injectable PrEP market <25% c.£4-5bn by 2030 of the 1.2 million people who could benefit from PrEP in the US are – First LA injectable PrEP administered currently taking PrEP2 ever
Slide 15: LA pipeline with opportunity for revenue renewal post dolutegravir LoE
LA pipeline with opportunity for revenue renewal post dolutegravir LoE1 Portfolio transition through decade with LA regimens c.£2bn in sales by 2026 Expected 2026 portfolio mix Post 2026 2021-26 LA pipeline growth drivers growth drivers h Dovato Self admin for treatment Cabenuva Ultra LA (ULA) for t
Slide 16: Innovators and disruptors
Innovators and disruptors Warren, Living with HIV, Alabama, USA 16
Slide 17: Most innovative pipeline in the industry
Search for remission and cure Most innovative pipeline in the industry Collaborations Prevention Cabotegravir long-acting1 Attachment inhibitor for highly experienced patients Rukobia (fostemsavir) New MOA3 ULA Maturation inhibitor portfolio1, 4 Capsid inhibitor1, 4 bNAb5 (N6LS)1, 4 Two-drug regimen
Slide 18: Industry-leading innovation creating new options for people living with HIV
Industry-leading innovation creating new options for people living with HIV First 2nd generation INSTI First approved two-drug regimen First attachment inhibitor for highly treatment experienced PLHIV First approved LA injectable regimen for HIV treatment First LA injectable for PrEP First head-to-h
Slide 19: The future of HIV treatment is LA
The future of HIV treatment is LA Daily reminder of HIV 7 in 10 PLHIV are interested in a LA treatment because of challenges with of PLHIV agreed that taking daily pills1 58% pills for HIV every day is a daily reminder of HIV in their life3 Fear of disclosure of PLHIV have hidden or 9 in 10 PLHIV pr
Slide 20: The future of HIV treatment is ULA
The future of HIV treatment is ULA Patricia, 53, living in Germany, diagnosed in 2005 – Drained from taking daily meds – Nervous about others If I can live for discovering her HIV status several months without burden, – Trusting relationship with her without thinking healthcare professional about it
Slide 21: The future of HIV treatment is self-administered
The future of HIV treatment is self-administered Eric, 39, living in New York – Not concerned about HIV status – Good relationship with his HCP and adherent to daily ARTs “ I would consider switching because of the convenience. – Wants control over where and You're not tied down, when he takes his m
Slide 22: The power of the integrase inhibitor
The power of the integrase inhibitor ViiV continues to lead the industry 100% 90% – INSTI are part of preferred or recommended 80% 70% share for the INSTI class ART regimens in HIV treatment guidelines across top-nine markets5 around the world1,2,3 70% – Gold standard status because of potency, 60%
Slide 23: Novel MOAs offer multiple options for development of new LA regimens
Novel MOAs offer multiple options for development of new LA regimens 2 4 6 VH4000422 Cabotegravir for PrEP Cabotegravir400 GSK3640254 Class: NRTTI Class: Maturation Inhibitor 1 Phase: Pre-clinical 3 Class: INSTI Class: INSTI Phase: I 5 Phase: II Phase: Registration GSK3810109A VH4023991 VH400280 Cab
Slide 24: The future of LA is in our innovative pipeline
The future of LA is in our innovative pipeline Multiple pathways to self-administration and ULA therapies Cabotegravir + Self-administered ULA Current phase bNAb (N6LS) Blocks HIV replication by attaching to CD4 binding site Phase II Maturation inhibitor1 Phase II Blocks protein processing late in t
Slide 25: Our strategic collaborations
Our strategic collaborations Business development Industry-academic collaboration Continuation of strong partnership Working together in unique industry-academic partnership to find a cure Exploring the possibility of ULA regimen Strategic collaboration and exclusive licensing agreement with Halozym
Slide 26: Expanding our portfolio of LA therapies with Halozyme
Expanding our portfolio of LA therapies with Halozyme – PH201 allows temporary expansion of subcutaneous space allowing larger volume subcutaneous injections – Capacity to increase volume increases opportunity for extended intervals between doses (every three months or more) – Exclusive use of Haloz
Slide 27: 20 years of integrase inhibitor success with Shionogi
20 years of integrase inhibitor success with Shionogi Exclusive collaboration on 3rd generation INSTI inhibitor has potential for ULA regimens Strong preliminary data Long half-life supports show VH184 has a high its potential for genetic barrier and administration of every resistance profile distin
Slide 28: The future of HIV prevention is LA
The future of HIV prevention is LA The PrEP landscape and unmet need Globally of people feel burdened by having to remember to 50% take an HIV prevention medication every day1 Lower PrEP use in key populations of PrEP users are white, with just 13% Latinx and 11% Black2. Black/African American and L
Slide 29: Major opportunities in PrEP
Major opportunities in PrEP Cabotegravir for PrEP: offers potential to transform the shape of the epidemic Cabotegravir LA superior to daily oral standard of care FDA Breakthrough Therapy and Priority Review designations Regulatory decision: 23 Jan 2022 Superior efficacy Cabotegravir superior in men
Slide 30: The future of HIV prevention is LA
The future of HIV prevention is LA Harvey, 31, living in Florida – Is aware of own risk for HIV and wants to protect himself – Tried oral PrEP a year ago, but “ It’s definitely going to save me time, I don’t have to go and pick up found it difficult to take every day prescriptions. I don’t and suffe
Slide 31: Maintaining HIV leadership beyond dolutegravir
Maintaining HIV leadership beyond dolutegravir INSTI-based LA regimens anchor current and future pipeline Data delivery Regimen selection Targeted launch window 2022-2023 2024 2025-2027 2027+ 2030+ 2022 By 2024 First self-administered ULA ULA Cab 400 Ph I Partner selection for long-acting regimen fo
Slide 32: Getting ahead of HIV
Getting ahead of Pioneering innovation for treatment and prevention HIV Mid single digit % sales CAGR 2021-26 Competitive execution capability driving performance Dovato and cabotegravir drive growth Cabotegravir LA portfolio replaces dolutegravir as foundational medicine Innovative LA pipeline powe
Slide 33: Q&A
Q&A Sylvia, Living with HIV, London 33